Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Foralumab

- PMLiVE

Tiziana shares promising results for intranasal foralumab in multiple sclerosis

The neurological disease affects approximately 2.8 million people worldwide

- PMLiVE

Tiziana to develop intranasal foralumab for type 1 diabetes

Approximately 4.7 million people in the UK are currently living with diabetes

- PMLiVE

Tiziana’s foralumab shows continued clinical improvement in secondary progressive MS

MS affects around 700,000 people in Europe and approximately 2.5 million people worldwide

- PMLiVE

Tiziana completes enrolment of first patient cohort in MS expanded access programme

Foralumab has already demonstrated positive results in patients with non-active SPMS

- PMLiVE

Tiziana starts enrolment in secondary progressive MS expanded access programme

MS affects around 700,000 people in Europe and approximately 2.5 million people worldwide

- PMLiVE

Biogen and Denali dose first patients with LRRK2 inhibitor in Parkinson’s disease study

Mutations in the LRRK2 gene are one of the most common causes of familial Parkinson’s disease

- PMLiVE

Tiziana’s Foralumab shows promise in second patient with secondary progressive MS

MS affects around 700,000 people in Europe and approximately 2.5 million people worldwide

- PMLiVE

Tiziana announces Brigham and Women’s hospital will receive ALS Association grant

ALS affects as many as 30,000 people in the US

- PMLiVE

Parkinson’s UK and Parkinson’s Foundation partner to accelerate drug development

Parkinson's disease is the fastest growing neurological condition worldwide, currently affecting 145,000 people in the UK

- PMLiVE

WHO publishes first position paper on optimising brain health

It is estimated that one in three people will develop a neurological disorder at some point in their life, making neurological disorders the leading cause of disability

- PMLiVE

Michael J Fox Foundation awards Koneksa second research grant

The grant will be used to evaluate whether digital biomarkers can help to predict the different stages of Parkinson’s disease

- PMLiVE

AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn

The agreement will focus on drug discovery, development and commercialisation of neurological diseases

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links